UA72535C2 - Analgesic and antipyretic pharmaceutical composition and method for its manufacture - Google Patents

Analgesic and antipyretic pharmaceutical composition and method for its manufacture Download PDF

Info

Publication number: UA72535C2
Authority: UA; Ukraine
Prior art keywords: homogenized; minutes; approximately; added; corn starch
Prior art date: 1999-07-28

Application number

UA2002021475A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-28

Filing date

2000-07-28

Publication date

2005-03-15

2000-07-28 Application filed filed Critical

2005-03-15 Publication of UA72535C2 publication Critical patent/UA72535C2/uk

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract description 4
238000000034 method Methods 0.000 title description 2
230000000202 analgesic effect Effects 0.000 title 1
230000001754 anti-pyretic effect Effects 0.000 title 1
239000002221 antipyretic Substances 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 17
OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 abstract description 17
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 abstract description 15
239000000203 mixture Substances 0.000 abstract description 15
229960005489 paracetamol Drugs 0.000 abstract description 15
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract description 8
239000003381 stabilizer Substances 0.000 abstract description 7
150000007524 organic acids Chemical class 0.000 abstract description 6
239000004480 active ingredient Substances 0.000 abstract description 4
CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 abstract description 3
235000010241 potassium sorbate Nutrition 0.000 abstract description 3
239000004302 potassium sorbate Substances 0.000 abstract description 3
229940069338 potassium sorbate Drugs 0.000 abstract description 3
229910019142 PO4 Inorganic materials 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
-1 poly(vinylpyrrolidone) Polymers 0.000 description 32
239000008187 granular material Substances 0.000 description 27
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
229920002261 Corn starch Polymers 0.000 description 18
239000008120 corn starch Substances 0.000 description 18
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 13
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
229920000168 Microcrystalline cellulose Polymers 0.000 description 11
235000019813 microcrystalline cellulose Nutrition 0.000 description 11
239000008108 microcrystalline cellulose Substances 0.000 description 11
229940016286 microcrystalline cellulose Drugs 0.000 description 11
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 10
229960004415 codeine phosphate Drugs 0.000 description 10
239000000454 talc Substances 0.000 description 10
229910052623 talc Inorganic materials 0.000 description 10
235000010323 ascorbic acid Nutrition 0.000 description 9
229960005070 ascorbic acid Drugs 0.000 description 9
239000011668 ascorbic acid Substances 0.000 description 9
239000008213 purified water Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
239000000843 powder Substances 0.000 description 8
229960004126 codeine Drugs 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 6
206010027145 Melanocytic naevus Diseases 0.000 description 6
208000007256 Nevus Diseases 0.000 description 6
235000021355 Stearic acid Nutrition 0.000 description 6
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
239000008117 stearic acid Substances 0.000 description 6
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
229940093915 gynecological organic acid Drugs 0.000 description 4
235000005985 organic acids Nutrition 0.000 description 4
229920002472 Starch Polymers 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
229960002065 drotaverine Drugs 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000008107 starch Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000002253 acid Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000012535 impurity Substances 0.000 description 2
229940072647 panadol Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
244000223014 Syzygium aromaticum Species 0.000 description 1
235000016639 Syzygium aromaticum Nutrition 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000011141 high resolution liquid chromatography Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000013112 stability test Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

UA2002021475A 1999-07-28 2000-07-28 Analgesic and antipyretic pharmaceutical composition and method for its manufacture UA72535C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU9902559A HU225779B1 (en)	1999-07-28	1999-07-28	Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
PCT/HU2000/000086 WO2001007024A2 (en)	1999-07-28	2000-07-28	Paracetamol and drotaverine containing composition

Publications (1)

Publication Number	Publication Date
UA72535C2 true UA72535C2 (en)	2005-03-15

Family

ID=90014235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002021475A UA72535C2 (en)	1999-07-28	2000-07-28	Analgesic and antipyretic pharmaceutical composition and method for its manufacture

Country Status (19)

Country	Link
EP (1)	EP1200088B1 (et)
AT (1)	ATE241983T1 (et)
AU (1)	AU6308800A (et)
BG (1)	BG65553B1 (et)
DE (1)	DE60003188T2 (et)
DK (1)	DK1200088T3 (et)
EA (1)	EA003779B1 (et)
EE (1)	EE04952B1 (et)
ES (1)	ES2197107T3 (et)
GE (1)	GEP20053581B (et)
HR (1)	HRP20020071B1 (et)
HU (1)	HU225779B1 (et)
ME (2)	ME00088B (et)
PL (1)	PL197749B1 (et)
PT (1)	PT1200088E (et)
RS (1)	RS50074B (et)
SI (1)	SI1200088T1 (et)
UA (1)	UA72535C2 (et)
WO (1)	WO2001007024A2 (et)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2232018C2 (ru) *	2002-10-09	2004-07-10	Открытое акционерное общество "Ирбитский химико-фармацевтический завод"	Спазмолитическое лекарственное средство
RU2252024C2 (ru) *	2003-04-22	2005-05-20	Гаврилов Андрей Станиславович	Способ получения спазмолитического лекарственного средства
UY29527A1 (es)	2005-05-13	2006-12-29	Schering Ag	Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
RU2704613C2 (ru) *	2014-11-11	2019-10-30	Д-Р Редди'С Лабораторис Лимитед	Фармацевтические препараты с фиксированной комбинацией доз обезболивающего и антиспазматического агентов
EP3520781A1 (en) *	2018-02-05	2019-08-07	Adamed sp. z o.o.	A pharmaceutical composition comprising metamizole, drotaverine, and caffeine
WO2021181262A1 (en) *	2020-03-09	2021-09-16	Almendro Properties And Trading Llp	Controlled release formulations comprising drotaverine or salt thereof
EP4140480A4 (en) *	2020-04-23	2024-06-12	Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd.	DRUG COMBINATION AND USE
BG113694A (bg)	2023-04-26	2024-10-31	"Адифарм" Еад	Фармацевтичен състав под формата на таблетка, съдържаща метамизол, кофеин и дротаверин и метод за нейното получаване
PL451289A1 (pl) *	2025-02-25	2026-04-13	Pikralida Spółka Z Ograniczoną Odpowiedzialnością	Kompozycja farmaceutyczna zawierająca naproksen i drotawerynę lub ich farmaceutycznie dopuszczalne sole, sposób jej wytwarzania oraz jej zastosowanie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3830353A1 (de) *	1988-09-07	1990-03-15	Basf Ag	Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5348745A (en) *	1989-05-09	1994-09-20	Miles Inc.	Aqueous granulation solution and a method of tablet granulation

1999
- 1999-07-28 HU HU9902559A patent/HU225779B1/hu not_active IP Right Cessation
2000
- 2000-07-28 EA EA200200211A patent/EA003779B1/ru not_active IP Right Cessation
- 2000-07-28 SI SI200030163T patent/SI1200088T1/xx unknown
- 2000-07-28 PT PT00949829T patent/PT1200088E/pt unknown
- 2000-07-28 AT AT00949829T patent/ATE241983T1/de active
- 2000-07-28 RS YUP-61/02A patent/RS50074B/sr unknown
- 2000-07-28 DE DE60003188T patent/DE60003188T2/de not_active Expired - Lifetime
- 2000-07-28 UA UA2002021475A patent/UA72535C2/uk unknown
- 2000-07-28 ME MEP-2008-185A patent/ME00088B/me unknown
- 2000-07-28 AU AU63088/00A patent/AU6308800A/en not_active Abandoned
- 2000-07-28 WO PCT/HU2000/000086 patent/WO2001007024A2/en not_active Ceased
- 2000-07-28 PL PL353209A patent/PL197749B1/pl unknown
- 2000-07-28 DK DK00949829T patent/DK1200088T3/da active
- 2000-07-28 EP EP00949829A patent/EP1200088B1/en not_active Expired - Lifetime
- 2000-07-28 EE EEP200200042A patent/EE04952B1/et not_active IP Right Cessation
- 2000-07-28 HR HR20020071A patent/HRP20020071B1/xx not_active IP Right Cessation
- 2000-07-28 ES ES00949829T patent/ES2197107T3/es not_active Expired - Lifetime
- 2000-07-28 ME MEP-185/08A patent/MEP18508A/xx unknown
- 2000-07-28 GE GE4754A patent/GEP20053581B/en unknown
2002
- 2002-01-30 BG BG106368A patent/BG65553B1/bg unknown

Also Published As

Publication number	Publication date
PL197749B1 (pl)	2008-04-30
SI1200088T1 (en)	2003-12-31
ATE241983T1 (de)	2003-06-15
BG65553B1 (bg)	2008-12-30
MEP18508A (en)	2010-06-10
EE200200042A (et)	2003-04-15
ME00088B (me)	2010-10-10
GEP20053581B (en)	2005-07-25
PL353209A1 (en)	2003-11-03
EP1200088B1 (en)	2003-06-04
DE60003188D1 (de)	2003-07-10
YU6102A (sh)	2005-03-15
DE60003188T2 (de)	2004-07-01
ES2197107T3 (es)	2004-01-01
EE04952B1 (et)	2008-02-15
EA003779B1 (ru)	2003-08-28
RS50074B (sr)	2009-01-22
HRP20020071A2 (en)	2003-12-31
EA200200211A1 (ru)	2002-08-29
HU225779B1 (en)	2007-08-28
HRP20020071B1 (hr)	2011-01-31
AU6308800A (en)	2001-02-13
WO2001007024A2 (en)	2001-02-01
PT1200088E (pt)	2003-10-31
HUP9902559A2 (hu)	2002-04-29
BG106368A (en)	2002-08-30
DK1200088T3 (da)	2003-09-22
HUP9902559A3 (en)	2003-05-28
HUP9902559D0 (en)	1999-10-28
WO2001007024A3 (en)	2001-03-29
EP1200088A2 (en)	2002-05-02

Publication	Publication Date	Title
CA2061520C (en)	2003-04-22	Delivery system for enhanced onset and increased potency
US5958979A (en)	1999-09-28	Stabilized medicaments containing thyroid hormones
AU2016378482A1 (en)	2018-07-12	Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
EP1643976B1 (en)	2008-12-03	Pharmaceutical formulation comprising levothyroxine sodium
CA2873230A1 (en)	2014-01-16	Laquinimod formulations without alkalizing agent
US10258562B2 (en)	2019-04-16	Effervescent tablet containing high level of aspirin
EP1322295A2 (en)	2003-07-02	Stabilization of solid drug formulations
AU2001294735A1 (en)	2002-06-27	Stabilization of solid drug formulations
UA72535C2 (en)	2005-03-15	Analgesic and antipyretic pharmaceutical composition and method for its manufacture
EP2934488B1 (en)	2018-10-17	A pharmaceutical composition containing candesartan cilexetil and amlodipine
JP6126780B2 (ja)	2017-05-10	ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤
CA2641575C (en)	2014-04-08	Stabilization of solid thyroid drug formulations
AU2001291244A1 (en)	2002-06-27	Stabilization of solid thyroid drug formulations
WO1999020276A1 (fr)	1999-04-29	Composition medicamenteuse stable
WO2015012365A1 (ja)	2015-01-29	医薬製剤
EP1736156A1 (en)	2006-12-27	STABILIZED 4-AMINO-5-CHLORO-N-¬(1R,3r,5S)-8-METHYL-8- AZABICYCLO¬3.2.1\|OCT-3-YL\|-2-¬1-METHYLBUT-2-YNYLOXY\|-BENZAMIDE CONTAINING COMPOSITION
ES2889598T3 (es)	2022-01-12	Uso de alcoholes de azúcar en composiciones de tibolona
KR20210052495A (ko)	2021-05-10	경구 투여용 의약 조성물
KR20210002542A (ko)	2021-01-08	갑상선 호르몬을 포함하는 흡입용 약학 건조 파우더 조성물(a pharmaceutical dry powder composition for inhalation comprising a thyroid hormone)
WO2007049626A1 (ja)	2007-05-03	カベルゴリン含有経口固形製剤
JPH02207A (ja)	1990-01-05	塩酸ブロムヘキシン含有製剤
HK1089094B (en)	2009-07-17	Pharmaceutical formulation comprising levothyroxine sodium
HK1213808B (en)	2019-11-08	A pharmaceutical composition containing candesartan cilexetil and amlodipine
HK1055260B (en)	2008-04-18	Stabilization of solid thyroid drug formulations